Axiom offers to pay biotechs to run drug programs while they keep 100% of assets

cjmaddison · x · 2026-11-22

AI drug-discovery firm Axiom says it's looking to partner with preclinical and clinical biotechs — and will pay them to run their drug programs, or partner on existing datasets. Axiom claims to cover the full loop: synthesis, potency, ADME, and 'the most predictive toxicity and safety assays in the world.'

The deal structure: the biotech retains 100% ownership of the asset, while Axiom shares ownership of the underlying data — a 'data-for-cash plus experimental outsourcing' model for programs that want to monetize development while keeping all upside.

Original post →

More from Apps

Apps channel →